Scorpius Holdings Completes Successful Public Offering of Shares
![Scorpius Holdings Completes Successful Public Offering of Shares](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Scorpius Holdings, Inc. Completes Public Offering of Shares
DURHAM, N.C. — Scorpius Holdings, Inc. (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), has successfully closed its underwritten public offering of 14,375,000 shares of common stock. This includes the full exercise of the underwriter’s over-allotment option. Each share of common stock was offered at a price of $1.00, resulting in gross proceeds of $14,375,000, prior to deducting underwriting discounts and offering expenses.
Use of Proceeds from the Offering
The net proceeds from this offering will primarily be allocated to funding working capital and facilitating general corporate purposes. This strategic funding is aimed at bolstering the company's operational capabilities and advancing its growth initiatives.
Role of ThinkEquity in the Offering
ThinkEquity acted as the sole book-running manager for this public offering. Their extensive expertise in capital markets has been instrumental in guiding Scorpius through this process.
Regulatory Compliance and Prospects
A registration statement on Form S-1 concerning the securities offered was filed with the Securities and Exchange Commission (SEC) and became effective earlier this month. The offering is being conducted strictly via a prospectus. Interested parties may obtain copies of the final prospectus directly from ThinkEquity located at 17 State Street, 41st Floor, New York, New York 10004.
About Scorpius Holdings, Inc.
Scorpius Holdings Inc. specializes in integrated large molecule contract development and manufacturing. The company is focused on propelling biologic and cell therapy programs from development to clinical application. Scorpius offers an extensive menu of analytical testing, process development, and manufacturing services designed for pharmaceutical and biotech companies, supported by its cutting-edge facilities in San Antonio, TX. With a commitment to transparency and high-quality biomanufacturing, Scorpius aims to foster strong collaborations with its partners.
Investor Relations Contacts
For investor inquiries, please contact:
David Waldman
+1 (919)-289-4017
investorrelations@nighthawkbio.com
Frequently Asked Questions
1. What was the amount raised in the public offering by Scorpius Holdings?
Scorpius Holdings raised a total of $14,375,000 from the public offering.
2. How will the proceeds from the offering be utilized?
The proceeds will primarily be used for working capital and general corporate purposes.
3. Who managed the public offering for Scorpius Holdings?
ThinkEquity acted as the sole book-running manager for the offering.
4. Where can one obtain a copy of the final prospectus?
Copies of the final prospectus can be obtained from ThinkEquity at their office in New York.
5. What type of organization is Scorpius Holdings?
Scorpius Holdings is an integrated contract development and manufacturing organization (CDMO) focusing on biologic and cell therapy programs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/